By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Constellation Pharmaceuticals 

215 First Street
Suite 200
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-714-0555 Fax: 617-859-2891


Key Statistics

Ownership: Private

Web Site: Constellation Pharma

Start Up

Company News
Constellation Pharma Appoints Adrian Senderowicz, M.D., As Senior Vice President And Chief Medical Officer 7/18/2017 6:50:13 AM
Jounce (JNCE)'s Number One Employee Rejoins Constellation Pharma as New CEO 5/25/2017 6:32:08 AM
Constellation Pharma Raises $55 Million In Mezzanine Financing 12/10/2015 11:31:25 AM
Constellation Pharma Mulls IPO After Genentech (RHHBY) Declines to Buy 8/25/2015 6:25:12 AM
Constellation Pharmaceuticals Initiates Clinical Development Of CPI-1205, A Novel Inhibitor Of EZH2, In Patients With Lymphoma 4/28/2015 8:36:32 AM
Constellation Pharmaceuticals Quietly Cuts 23 Employees as Genentech (RHHBY)'s Decision Looms 1/19/2015 6:25:09 AM
Constellation Pharmaceuticals and the University of Pittsburgh School of Medicine Receive Cystic Fibrosis Foundation Research Grant 10/10/2013 9:36:10 AM
Constellation Pharmaceuticals Announces New Preclinical Data on Novel BET Bromodomain Inhibitors Published in The Journal of Experimental Medicine 10/8/2013 10:38:19 AM
Constellation Pharmaceuticals Initiates Clinical Development of CPI-0610, a Novel BET Protein Bromodomain Inhibitor, in Patients With Lymphoma 9/10/2013 9:32:50 AM
Constellation Pharmaceuticals and The Leukemia & Lymphoma Society Partner to Develop Novel BET Inhibitor for the Treatment of Hematologic Malignancies 9/20/2012 10:22:54 AM